Which has the lower trailing P/E, ARQT or ATRC?

ARQT has the lower trailing P/E: ARQT trades at 115.68 and ATRC at 258.13. P/E is one valuation measure and does not by itself establish which business is cheaper.

Is ARQT or ATRC more profitable?

ARQT runs the higher net margin — ARQT at 6.15% versus ATRC at 1.85%.

How have ARQT and ATRC total returns compared?

Over the past 5 years, ARQT delivered -0.28% and ATRC delivered -4.06% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs AtriCure, Inc. (ATRC)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and AtriCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$3.02B

$24.12HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT

ATRC

AtriCure, Inc.

$2.79B

$54.78HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT

Total return — ARQT vs ATRC

growth of $100 · dividends reinvested · last 7y

ARQT +15.4% (+2.1%/yr)ATRC +48.7% (+5.8%/yr)ATRC compounded faster over this window

ARQT ATRC

ARQT vs ATRC: by the numbers

•ARQT is the larger company ($3.02B vs $2.79B market cap).
•ARQT trades at the lower trailing earnings multiple (115.68 vs 258.13 P/E), one valuation lens rather than an overall verdict.
•ARQT converts more revenue to profit (6.15% vs 1.85% net margin).

Metrics side by side

Valuation

Metric	ARQT	ATRC
P/E ratio	115.68	258.13
Forward P/E	48.52	N/A
P/S ratio	6.50	4.89
P/B ratio	13.68	5.40
EV / EBITDA	83.25	77.40
FCF yield	1.30%	1.84%

Profitability

Metric	ARQT	ATRC
Gross margin	91.14%	76.16%
Operating margin	-3.25%	2.44%
Net margin	6.15%	1.85%
ROE	12.93%	2.04%
ROIC	9.95%	2.04%

Growth (annualized)

Metric	ARQT	ATRC
Revenue CAGR (5Y)	N/A	18.57%
Total return CAGR (5Y)	-0.28%	-4.06%

Frequently asked

Which has the lower trailing P/E, ARQT or ATRC?: ARQT has the lower trailing P/E: ARQT trades at 115.68 and ATRC at 258.13. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is ARQT or ATRC more profitable?: ARQT runs the higher net margin — ARQT at 6.15% versus ATRC at 1.85%.
How have ARQT and ATRC total returns compared?: Over the past 5 years, ARQT delivered -0.28% and ATRC delivered -4.06% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full ATRC analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio AtriCure P/E ratio Arcutis Biotherapeutics ROE AtriCure ROE Arcutis Biotherapeutics operating margin AtriCure operating margin Arcutis Biotherapeutics revenue growth AtriCure revenue growth Arcutis Biotherapeutics free cash flow AtriCure free cash flow

Arcutis Biotherapeutics & AtriCure appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.